NIMH Toxicological Evaluation of Novel Ligands Program

NIMH 新型配体毒理学评估计划

• 批准号: 9162051
• 负责人: HANNA NG
• 金额: $ 5.24万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9162051
• 关键词: Adverse effects; Binding; Biochemical; Biological Assay; Biotechnology; Blood - brain barrier anatomy; Brain imaging; Clinical; Clinical Research; Code; Complement; Contracts; Data; Development; Dose; Dose-Limiting; Evaluation; Funding; Goals; Human; Image; Investigational New Drug Application; Ligands; Maximum Tolerated Dose; Mental disorders; National Institute of Mental Health; Neuraxis; Pharmaceutical Preparations; Pharmacologic Substance; Plasma; Positron-Emission Tomography; Preclinical Drug Evaluation; Psychotropic Drugs; Radiopharmaceuticals; Research; Research Personnel; Resources; Safety; Sampling; Schedule; Source; Therapeutic Agents; Toxic effect; Toxicology; United States National Institutes of Health; analog; base; cost effective; design; in vivo; novel; programs; receptor; single photon emission computed tomography

The purpose of the NIMH Toxicological Evaluation of Novel Ligands Program is to accelerate the discovery, development, and application of novel ligands for imaging in humans. The program will also facilitate the discovery and development of novel psychoactive agents for clinical research and as potential therapeutic agents for the treatment of mental disorders. This initiative will provide a critical resource that complements NIMH’s existing Psychoactive Drug Screening Program for pharmacological characterization of novel compounds in binding assays for receptors, channels, and transporters in the central nervous system and in biochemical assays to assess functional activity. The Toxicological Evaluation of Novel Ligands Program will also complement the initiative to accelerate the Development of Novel PET and SPECT Ligands for Brain Imaging for use in human studies. Efforts of these activities will be coordinated to establish a pipeline for the rapid and cost-effective development of novel ligands for clinical studies of mental disorders.

NIMH新配体毒理学评估计划的目的是加速人类成像新配体的发现、开发和应用。该计划还将促进发现和开发用于临床研究的新型精神活性药物，并将其作为治疗精神障碍的潜在治疗药物。这一倡议将提供一个关键资源，补充NIMH现有的精神活性药物筛选计划，用于在中枢神经系统受体、通道和转运体的结合分析以及用于评估功能活性的生化分析中对新化合物进行药理学表征。新配体的毒理学评估计划还将补充加快开发用于人体研究的脑部成像的新型PET和SPECT配体的倡议。将协调这些活动的努力，以建立一条管道，快速和具有成本效益地开发用于精神障碍临床研究的新配体。